Investor Relations

Diagonal Bio is a Swedish biotech company that has developed a ground breaking universal technology platform for the quick and accurate detection of genetic markers in genetic material (DNA and RNA).

Background

Diagonal Bio AB is a Swedish medical technology company founded in 2020 with the vision of limiting the spread of infectious diseases by creating a user-friendly, cost-effective diagnostic platform with high accuracy. Based on its patented technology, Diagonal Bio plans to develops a diagnostic systems, PANVIRAL™, that have the potential to fulfill the vision and thereby facilitate the challenge of rapidly and accurately identifying genetic markers for infectious diseases.

Diagonal Bio’s patented technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®).

Diagonal Bio’s patented technology

Diagonal Bio’s patented technology offers the same accuracy as today’s leading diagnostic method, PCR, but is not dependent on complicated logistics or large central laboratories and is therefore significantly faster and more cost-effective. With the help of the Company’s technology, today’s and future infectious diseases can be diagnosed within 10–15 minutes of sampling, in connection with a visit to, for example, a primary care unit.

Diagonal Bio’s platform technology can also be used for other purposes outside the market segment for in-vitro diagnostics, for example as a general laboratory equipment quick, accurate and cost-effective identification of genetic markers (LAMPlify®). This, too, with the same high accuracy as today’s PCR-based techniques, but in a significantly faster, simpler and more cost-effective.

Press Releases

Kommuniké från årsstämma den 11 juni 2024 i Diagonal Bio AB

Regulatory

Idag, den 11 juni 2024, hölls årsstämma i Diagonal Bio AB. Nedan följer en sammanfattning av de beslut som fattades.

Read more

Bulletin from the Annual General Meeting on 11 June 2024 in Diagonal Bio AB

Regulatory

Today, on 11 June 2024, the Annual General Meeting of Diagonal Bio AB was held. A summary of the adopted resolutions follows below.

Read more

Diagonal Bio AB first quarter (Q1 2024)

Regulatory

“The end of last year was marked by our focus on creating the business platform to generate the company’s initial revenue in 2024. We continue and gear up on the set path with a focus on generating revenue”.

Read more

Diagonal Bio appoints new CFO

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) has appointed Fata Mrsic as the new Chief Financial Officer (CFO). Fata will assume the position on June 14, 2024, and be part of the Management Team.

Read more

Diagonal Bio announces strategic pilot study with Löberöds Hästklinik

Regulatory

Diagonal Bio AB (publ) (“Diagonal Bio” or “the Company”) is pleased to announce a significant new collaboration with Löberöds Hästklinik, led by renowned sporthorse veterinarian Lisa Lidbeck. The agreement, set to last an initial term of three months, will involve a pilot testing program focused on utilizing Diagonal Bio’s platform technology, LAMPlify®, for the detection of respiratory viral infections in sporthorses.

Read more

Revisor

Mazars, Revision

Scheelevägen 17
223 63 Lund
Sweden

Contact us

Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com

Certified advisor

Svensk Kapitalmarknadsgranskning AB
www.skmg.se

Phone: +46 (0)8 913 008
E-mail: ca@skmg.se

Issuer

Nordic Issuing AB
Stortorget 3
211 22 Malmö